CHU Jean Verdier   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Bobigny France

Organization Overview

First Clinical Trial
2010
NCT01022658
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

AP-HP_Hôpital Jean Verdier | APHP-Hôpital Jean Verdier | CHU-Jean Verdier | CHU Jean VERDIER | CHU Jean Verdier - APHP | Hôpital Jean Verdier | Hospital Jean Verdier | Jean Verdier Hospital | Jean Verdier Hospital - Department of Endocrinology-Diabetology-Nutrition

Active Ingredients

Drugs in Phase 4 Trials (1)

nicotine (nicorette) (1 trial)

Drugs in Phase 3 Trials (1)

estrogen (1 trial)

Drugs in Phase 2 Trials (3)

lenvatinib (lenvima) (1 trial)

nivolumab (opdivo) (1 trial)

saxagliptin (onglyza) (1 trial)

Drugs in Other Trials (4)

human choriogonadotropin alfa (hCG) (1 trial)

insulin human (humulin) (1 trial)

oxygen (1 trial)

triptorelin (Trelstar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 2)

Glucose Intolerance (Phase 2)

Infertility (Phase 3)

Tobacco Use Disorder (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 9